VELMARA BIO
Restoring immune tolerance with next-generation IL-2 mutein therapies for patients who need it most.
We believe that every patient, no matter how rare their condition, deserves the chance at a life free from relentless autoimmunity.
of rare autoimmune patients experience little to no response from standard treatments
approved therapies that currently exist for many ultra-rare autoimmune diseases
Our Science
Autoimmune diseases occur when the body’s immune system mistakenly attacks its own tissues. Traditional treatments often suppress immunity broadly, leaving patients vulnerable to infections and side effects.
Velmara Bio takes a different approach. Our proprietary IL-2 mutein platform re-engineers the interleukin-2 pathway to precisely expand regulatory T cells (Tregs), restoring immune tolerance without broadly suppressing immunity.
Enhances Treg activity to reset immune balance.
Engineered to reduce off-target signaling and toxicity.
Tailored for individuals with ultra-rare, treatment-resistant autoimmune conditions.
Pipeline
First-in-class IL-2 mutein therapy for refractory autoimmune encephalitis.
Learn More
Preclinical program expanding into broader rare immune disorders.
Learn More